MEDIA STATEMENT

PHILOGEN SpA ANNOUNCES THE SUCCESSFUL GMP PRODUCTION OF PHC-102 FOR THE IMAGING OF RENAL CELL CARCINOMA AND OTHER CARBONIC ANHYDRASE EXPRESSING TUMORS.

Siena, Italy, July 25th 2016. Philogen S.p.A., announced today, through its fully owned subsidiary Philochem AG, the successful GMP-compliant production of PHC-102, a ⁹⁹mTc-labeled small molecule ligand of Carbonic Anhydrase IX (CAIX), for the non-invasive detection of renal cell carcinoma and other CAIX-expressing tumours.

CAIX is a hypoxia-inducible enzyme highly overexpressed in renal cell carcinoma and other several tumor types. CAIX has so far been imaged using antibody-based products. However, macromolecular radiotracers such as antibodies in IgG format typically exhibit slow clearance from the blood, exposing patients to unnecessarily high radiation burden. Moreover, monoclonal antibodies may be immunogenic, which can preclude repeated administration for routine diagnostic procedures.

PHC-102 has been shown, in preclinical model, to reach its target much more rapidly and efficiently than antibody-based radiotracers. High tumor:organs and tumor:blood ratio at early time points suggest that PHC-102 has the potential to improve the detection of hypoxic region and small tumor masses and decrease the exposure of patients to radiation.

Dr. Duccio Neri, co-founder and CEO of the Philogen group, commented: “We are pleased with the progress of the PHC-102 program, as this product has the potential to outperform antibody-based products for the detection of renal cell carcinoma lesions and other CAIX-positive malignancies. The next important milestone for the program will be the clinical investigation of PHC-102, in the frame of the EUROSTARS “ATRI” project, coordinated by Philochem AG.”


About the Philogen group
Philogen is a clinical-stage biotechnology company engaged in the discovery and development of novel biopharmaceutical products. Philogen’s strategy is to deliver bioactive agents, for example cytokines or drugs to the site of disease using antibodies and ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and also pre-clinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem in Zürich, Switzerland. Philogen is independently owned, and has signed agreements with several major pharmaceutical companies. For more information, please visit www.philogen.com

Reference